ALSO NOTED: YM BioSciences gets cancer drug approval in India; Takeda starts testing of diabetes treatment; and much more...

> YM BioSciences has received approval from India's Drug Controller General to market nimotuzumab, an anti-EGFr monoclonal antibody, for the treatment of head & neck cancer. Release

> Takeda has announced that subsidiary Takeda Global Research & Development Center has kicked off Phase III testing of TAK-536, a potential type 2 diabetes treatment. Release

> Berlex is recalling a single lot of its intravenous X-ray contrast agent, Ultravist Injection, due serious safety concerns related to the presence of particulate matter in conjunction with crystallization. Report

> Eli Lilly and Alcon will co-promote ruboxistaurin mesylate (Arxxant)--a treatment for moderate to severe nonproliferative diabetic retinopathy--in the U.S and Puerto Rico. Release

And Finally... A report from the Institute of Medicine states that 1.5 million Americans are harmed or killed by due to medications errors. Article

Suggested Articles

Passage Bio filed to raise $125 million in its IPO. Now, it has outraised that goal by $91 million with a $216 million Wall Street debut.

The ruling reflects the judge’s belief that the FDA’s interpretation of the law on clinical trial reporting “is unlawful and must be set aside.”

Trutino will apply a platform designed to yield safer, more effective cytokines to the discovery of three oncology drugs for Boehringer.